Authors
Latest:
Bone-Targeted Therapy in Early Breast CancerIn this article, we describe the role of bone-targeted therapies, specifically for managing early breast cancer, by reviewing their bone-specific and cancer-specific benefits.
Latest:
Bone-Targeted Therapy in Early Breast CancerIn this article, we describe the role of bone-targeted therapies, specifically for managing early breast cancer, by reviewing their bone-specific and cancer-specific benefits.
Latest:
Bone-Targeted Therapy in Early Breast CancerIn this article, we describe the role of bone-targeted therapies, specifically for managing early breast cancer, by reviewing their bone-specific and cancer-specific benefits.
Latest:
Bone-Targeted Therapy in Early Breast CancerIn this article, we describe the role of bone-targeted therapies, specifically for managing early breast cancer, by reviewing their bone-specific and cancer-specific benefits.
Latest:
Cancer-Related Fatigue Outcome Measures in Integrative Oncology: Evidence for Practice and Research RecommendationsThis review article written by Danielle Gentile, PhD, et al, reviews the management of cancer-related fatigue in integrative oncology.
Latest:
Pros and Cons of Dietary Strategies Popular Among Cancer PatientsThis article discusses some of the popular diets that cancer patients pursue, and the positive and negative aspects associated with these diets.
Latest:
Considerations in the Care of Non–Small-Cell Lung Cancer: The Value ImperativeThis article discusses ways in which the oncologist can incorporate value into the management of patients with lung cancer and comply with the underlying principles of the Choose Wisely Campaign, as well as recent ASCO and ESMO initiatives, to bend the cost curve downwards while maintaining efficacy.
Latest:
Considerations in the Care of Non–Small-Cell Lung Cancer: The Value ImperativeThis article discusses ways in which the oncologist can incorporate value into the management of patients with lung cancer and comply with the underlying principles of the Choose Wisely Campaign, as well as recent ASCO and ESMO initiatives, to bend the cost curve downwards while maintaining efficacy.
Latest:
Role of Temozolomide in the Treatment of Cancers Involving the Central Nervous SystemIn this article, we review the role of temozolomide in the management of patients with primary brain tumors, brain metastases, leptomeningeal carcinomatosis, and other selected CNS cancers.
Latest:
TNFR2's Role in Influencing Tumor TissueDr. Denise Faustman spoke with Cancer Network about TNFR2 and its emerging role in understanding regulatory T-cell behavior.
Latest:
Epigenetics, BRCA, and Inherited Cancers: Dr. Newman Connects the DotsDr. William Newman spoke with Cancer Network about the roles of epigenetic silencing in heritable cancer syndromes.
Latest:
ctDNA Positivity Appears to Predict Risk of Recurrence, Benefit from Adjuvant Chemotherapy in Resectable CRCAn expert from Natera discusses ctDNA’s predictive and prognostic value in resectable colorectal cancer based on data from the GALAXY cohort of the CIRCULATE-JAPAN platform study.
Latest:
Bacterial Therapy May Be Promising in Cancer PatientsDr. Filip Janku speaks with Cancer Network about a phase I clinical trial investigating the use of bacterial clostridium novyi-NT in solid tumors.
Latest:
Managing CAR T-Cell Therapy in Patients With Hematologic MalignanciesStephanie Jackson, MSN, RN speaks with Cancer Network about the role oncology nurses play in managing patients with hematologic malignancies who are undergoing CAR T-cell therapy.
Latest:
Panitumumab Helps Colorectal Cancer Patients Get to SurgeryThe VOLFI trial enrolled 105 patients with RAS wild-type metastatic colorectal cancer.
Latest:
Immunotherapeutic Approaches to the Management of Head and Neck CancerExperts discuss the PD-1 checkpoint inhibitors nivolumab and pembrolizumab in the management of head and neck cancer, and how to choose between them.
Latest:
Immunotherapeutic Approaches to the Management of Head and Neck CancerExperts discuss the PD-1 checkpoint inhibitors nivolumab and pembrolizumab in the management of head and neck cancer, and how to choose between them.
Latest:
Immunotherapeutic Approaches to the Management of Head and Neck CancerExperts discuss the PD-1 checkpoint inhibitors nivolumab and pembrolizumab in the management of head and neck cancer, and how to choose between them.
Latest:
Strategies for the Optimal Management of Dyspnea in Cancer Patients With Advanced IllnessIn this article, Dr. Mona Patel discusses how to best manage dyspnea in cancer patients, with both pharmacologic and nonpharmacologic approaches.
Latest:
Identifying Molecular Markers of Relapse in Myelodysplastic SyndromeIn this month's installment of Ask the PI, ONCOLOGY spoke with Meagan A. Jacoby, MD, PhD, and Matthew Walter, MD, about their findings and what they might mean for practicing oncologists.
Latest:
Identifying Molecular Markers of Relapse in Myelodysplastic SyndromeIn this month's installment of Ask the PI, ONCOLOGY spoke with Meagan A. Jacoby, MD, PhD, and Matthew Walter, MD, about their findings and what they might mean for practicing oncologists.
Latest:
COUNTERPOINT-Prostate Cancer Genomic Analysis: Routine or Research Only?In this side of the Point/Counterpoint, Drs. Kelly and Knudsen state that limitations exist for guiding therapeutic treatment with genomic testing in prostate cancer patients.
Latest:
Mechanisms and Treatment for Cancer- and Chemotherapy-Related Cognitive Impairment in Survivors of Non-CNS MalignanciesThis article reviews the evidence for the putative mechanisms of cancer-related cognitive impairment by examining clinical and preclinical models, primarily those associated with chemotherapy, as well as treatment options and practical clinical advice.
Latest:
Mechanisms and Treatment for Cancer- and Chemotherapy-Related Cognitive Impairment in Survivors of Non-CNS MalignanciesThis article reviews the evidence for the putative mechanisms of cancer-related cognitive impairment by examining clinical and preclinical models, primarily those associated with chemotherapy, as well as treatment options and practical clinical advice.
Latest:
Mechanisms and Treatment for Cancer- and Chemotherapy-Related Cognitive Impairment in Survivors of Non-CNS MalignanciesThis article reviews the evidence for the putative mechanisms of cancer-related cognitive impairment by examining clinical and preclinical models, primarily those associated with chemotherapy, as well as treatment options and practical clinical advice.
Latest:
Mechanisms and Treatment for Cancer- and Chemotherapy-Related Cognitive Impairment in Survivors of Non-CNS MalignanciesThis article reviews the evidence for the putative mechanisms of cancer-related cognitive impairment by examining clinical and preclinical models, primarily those associated with chemotherapy, as well as treatment options and practical clinical advice.
Latest:
Gonadotropin-Releasing Hormone Antagonists in Prostate CancerThis article reviews the mechanism of action between GnRH agonists and antagonists and the studies that led to the approval of degarelix, as well as its potential risks and benefits, particularly when it comes to cardiovascular health.
Latest:
Gonadotropin-Releasing Hormone Antagonists in Prostate CancerThis article reviews the mechanism of action between GnRH agonists and antagonists and the studies that led to the approval of degarelix, as well as its potential risks and benefits, particularly when it comes to cardiovascular health.
Latest:
Managing Afib in Cancer Patients Taking BTK InhibitorsCancer Network speaks with Dr. Leon Ptaszek about managing cancer patients who have atrial fibrillation and are being treated with BTK inhibitors.
Latest:
KATHERINE Results Back New Adjuvant Standard for HER2+ Breast CancerDr. Charles Geyer discusses the phase III KATHERINE trial, which compared ado-trastuzumab emtansine vs trastuzumab in HER2-positive early breast cancer.
